Cidara Therapeutics Inc reports results for the quarter - Earnings Summary

Cidara Therapeutics

08/11/2024 21:04

* Cidara Therapeutics Inc  CDTX.OQ  reported a quarterly
adjusted
loss of $2.45​​ per share for the quarter , lower than the same
quarter last year, when the company reported EPS of $-1.80.  The
mean expectation of three analysts for the quarter was for a
loss of $4.25 per share. Wall Street expected results to range
from $-5.66 to $-1.87 per share.
    * Reported revenue was zero​; analysts expected $433.33
thousand. 
    * Cidara Therapeutics Inc's reported EPS for the quarter was
a
loss of $2.45​.
    * The company reported a quarterly loss of $15.99 million.
    * Cidara Therapeutics Inc shares had risen by 22.0% this
quarter and lost 17.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 21.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cidara
Therapeutics Inc is 29.00 
This summary was machine generated from LSEG data November 8 at
09:04 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -4.25          -2.45          Beat
 Jun. 30 2024      -3.22          -1.39          Beat
 Mar. 31 2024      -0.20          -2.28          Missed
 Dec. 31 2023      -2.07          -0.80          Beat